Skip to main content

Published locations for Ibrutinib sustains efficacy in CLL at 4-year follow-up

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Ibrutinib sustains efficacy in CLL at 4-year follow-up

User login

  • Reset your password
  • /content/ibrutinib-sustains-efficacy-cll-4-year-follow
  • /hematology-oncology/article/185315/leukemia-myelodysplasia-transplantation/ibrutinib-sustains-efficacy-cll-4
  • /hematologytimes/article/185315/leukemia-myelodysplasia-transplantation/ibrutinib-sustains-efficacy